You will be shown a claim about public health, and the abstract of a biomedical research paper. Each sentence from the abstract will be on a separate line. Your task is to return a JSON object with two fields:

- "verdict": The fact-checking verdict. If the information in the abstract supports the claim, write "SUPPORT". If the abstract contradicts the claim, write "CONTRADICT". If the abstract does not provide enough information to arrive at a verdict, write "NEI" (for "not enough information").
- "evidence": An array of sentences providing evidence for the verdict. Please copy all relevant sentences verbatim from the abstract. If the verdict was "NEI", then return an empty array.

For instance, if the model were given the claim "wearing masks can prevent the spread of COVID", the output might be
{
  "verdict": "SUPPORT",
  "evidence": ["Our findings indicate that mass mask-wearing reduces the transmission rate for COVID-19."]
}

Claim: Favipiravir, an antiviral drug used for influenza in Japan, is currently being studied in humans for treating COVID-19 in over 30 clinical trials (as of July 31, 2020). It is not known whether it is safe or helpful for this disease.

Abstract:
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) has been reported in China since December 2019.
More than 16% of patients developed acute respiratory distress syndrome, and the fatality ratio was about 1%-2%.
No specific treatment has been reported.
Herein, we examine the effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19.
Patients with laboratory-confirmed COVID-19 who received oral FPV (Day 1: 1600 mg twice daily; Days 2-14: 600 mg twice daily) plus interferon (IFN)-&#945; by aerosol inhalation (5 million U twice daily) were included in the FPV arm of this study, whereas patients who were treated with LPV/RTV (Days 1-14: 400 mg/100 mg twice daily) plus IFN-&#945; by aerosol inhalation (5 million U twice daily) were included in the control arm.
Changes in chest computed tomography (CT), viral clearance, and drug safety were compared between the two groups.
For the 35 patients enrolled in the FPV arm and the 45 patients in the control arm, all baseline characteristics were comparable between the two arms.
A shorter viral clearance time was found for the FPV arm versus the control arm (median (interquartile range, IQR), 4 (2.5-9) d versus 11 (8-13) d, P < 0.001).
The FPV arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.43% versus 62.22% (P = 0.004).
After adjustment for potential confounders, the FPV arm also showed a significantly higher improvement rate in chest imaging.
Multivariable Cox regression showed that FPV was independently associated with faster viral clearance.
In addition, fewer adverse reactions were found in the FPV arm than in the control arm.
In this open-label nonrandomized control study, FPV showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance; if causal, these results should be important information for establishing standard treatment guidelines to combat the SARS-CoV-2 infection.
{"verdict": "SUPPORT", "evidence": ["Herein, we examine the effects of Favipiravir (FPV) versus Lopinavir (LPV)/ritonavir (RTV) for the treatment of COVID-19."]}